Health and Well-being Week
Agenda2025 business exchange programme‘Visionary Exchange'
Japan Association for the 2025 World Exposition
We are pleased to organise a speech and discussion event, as well as a lunch networking event, on the theme of the Agenda programme ‘Health and Well-being’, entitled ‘Visionary Exchange’, as part of the Agenda2025 programme.This gathering aims to include business delegations, universities, scientists, government officials, Agenda2025 panelists, and relevant Japanese leaders from government, industry, and academia. Participants will engage in keynote addresses and networking sessions aligned with each Theme's focus.（Invitation only）
Business Exchange
- Well-being
- Healthy life expectancy
- Regenerative medicine/cell, therapy/gene therapy
| Transmission of simultaneous interpretation | Provided |
|---|---|
| Language of interpretation | Japanese and English |
This programme is invitation only.
-
Agenda2025
Organised Programme
- * Programme times and content are subject to change. Any changes will be announced on this website and via the ticket booking system.
- * The schedule is subject to change depending on the organiser's circumstances.
- Time and
Date of
the event -
-
2025.06.27[Fri]
10:30 ～ 13:30
(Venue Open 10:00)
-
- Venue
- EXPO Salon
Programme details
‘Visionary Exchange’ is an invitation-only programme that will be held three times, and this is the second programme. To establish a meaningful forum that fosters ongoing collaboration among stakeholders, both during and beyond the Theme Weeks, thereby building shared understanding and connections that contribute to designing the future of society.
10:00 Venue open/Welcome coffee
10:30-12:00 PartⅠ：Speech and discussion
Main Topic:Health and Well-being(How do we realize a society where the well-being of each person resonates?)
・Lead Navigator：Seiji Inada（Agenda2025 Advisor）
1. Global Health Equity and Access for All
Speakers:Paulo Gadelha(Coordinator of the Fiocruz Strategy for the 2030 Agenda =EFA 2030, Brazil)
Ionescu Octavian（Romanian's National Institute for Research and Development for Microtechnologies）
Pierre Van Damme（MD, PhD,Director of the Centre for the Evaluation of Vaccination =CEV, University of Antwerp, Belgium）
2. Cutting-Edge Medical Innovations & Future Healthcare Systems: Personalization, Equity & Planetary Health
Speakers：Arita Dubnika（Assist. Prof., Dr.sc.ing., Direction Leader, Institute of Biomaterials and Bioengineering, Riga Technical UniversityFaculty of Natural, Latvia）
Carmen van Vilsteren（Chair of the Top Sector Life Sciences & Health, The Netherlands）
Jakub Hlávka（Director of the Health Economics, Policy and Innovation Institute (HEPII) at Masaryk University, Czech Republic）
Michio Tanaka（VP, Medical, AstraZeneca, United Kingdom）
3. Fostering a Culture of Well-being – Work, Education, and Mental Health
Speakers:Charmaine Gauci（Superintendent of Public Health and Director General of Health Regulation at the Ministry for Health, Republic of Malta）
Marwan Al Kaabi（Chief Executive Officer - Sheikh Shahbout Medical City, a PureHealth Entity Company, United Arab Emirates）
12:00-13:30 Part Ⅱ： Lunch networking
Cast
Moderator
Seiji Inada
Agenda2025Advisor
Seiji Inada blends government insight with global business acumen. After shaping foreign and national security policy at Japan’s Ministry of Foreign Affairs and the Prime Minister’s Office, he honed his commercial edge with a global consulting firm. He then steered high‑level initiatives at the World Economic Forum and became Japan Representative for Eurasia Group, advising C‑suites on geopolitical risk. Now Managing Director at FGS Global, he counsels public institutions and global companies integrate geopolitical realities into long-term business strategy. He also acts as an Agenda 2025 Advisor for Expo 2025 Osaka‑Kansai, driving forward‑looking dialogue on innovation and the future of society. He continues to counsel several private-sector organizations.
View Profile
Close
close
Speakers
Paulo Gadelha
Oswaldo Cruz Foundation, Fiocruz Strategy for the 2030 Agenda (EFA 2030/Fiocruz), Brazil
Dr. Paulo Gadelha (M.D.), former President of the Oswaldo Cruz Foundation - Fiocruz (from 2009 to 2016) and Brazilian representative under the United Nations 10-Member-Group of High-level Representatives (from 2016 to 2020). Dr. Gadelha coordinates the Fiocruz Strategy for 2030 Agenda (EFA 2030/Fiocruz) since its establishment in 2017, contributing to Brazilian federal planning, and the territorialization of the SDGs at the local level.
View Profile
Close
close
Pierre Van Damme
Director Vaccinopolis and Centre for the Evaluation of Vaccination, University of Antwerp
Pierre Van Damme (PhD in epidemiology and public health, 1994) is emeritus professor at University of Antwerp, after a career of full professorship since 2000.
He is for more than 35 years active in vaccine trial and infectious disease research, and conducted as PI or co-PI more than 550 vaccine trials, and authored more than 600 peer-reviewed papers.
He was (since 2000) full professor in Vaccinology at the University of Antwerp, Faculty of Medicine and Health Sciences, and teaches vaccinology in national and international courses. Pierre Van Damme is heading the Centre for the Evaluation of Vaccination (CEV, University of Antwerp), which he founded in 1994, and director of Vaccinopolis, a unique facility in Europe for vaccine trials and human challenge studies. The CEV is a WHO Collaborating Centre for the WHO European Region for the control and prevention of infectious diseases. With Arnaud Marchant he set up the recently founded European Plotkin Institute for Vaccinology, an initiative to accelerate the evaluation of vaccines for pandemic and endemic pathogens. He recently was awarded with the IVI-SK Bioscience award for the contribution to the development and delivery of vaccines for global health (Seoul, 2025).
View Profile
Close
close
Arita Dubnika
Assist. Prof., Dr.sc.ing., Direction Leader, Institute of Biomaterials and Bioengineering, Riga Technical UniversityFaculty of Natural
Dr.sc.ing. Arita Dubnika has 15 years of expertise in bone biomaterials development, tissue engineering, and bioactive agent delivery systems. She specializes in the development of advanced biomaterials, including autologous blood derivatives like platelet-rich fibrin for tissue engineering. Her research also focuses on antimicrobial and anti-inflammatory properties, with applications in oral and maxillofacial surgery. Since 2020, Dr. Dubnika has been the leader of the "Materials in vitro" direction at the Riga Technical University, Institute of Biomaterials and Bioengineering, Latvia. She has received Julia Polak European Doctorate Award for her contributions to regenerative medicine and Baltic American Freedom Fellowship for research studies at Stanford University, USA. Dr.Dubnika is leading numerous international collaborations with academia, clinics, and industry, coordinating several research and commercialization projects. She also supervises Postdoctoral and PhD students, actively contributing to the next generation of researchers in biomaterials and regenerative medicine. As a young researcher in Latvia, she has secured more than €30M for biomaterials research in the region.
View Profile
Close
close
Carmen van Vilsteren
Chair of the Top Sector Life Sciences & Health, The Netherlands
Carmen van Vilsteren is Chair of the Top Sector Life Sciences & Health. She has earned her spurs in the medical industry, at Philips and Thermofisher and is also a serial entrepreneur including as CEO and co-founder of Microsure, a TU/e spin-off in the field of micro-surgery robots. She is now mainly committed to helping other startups as a mentor and investor. She was also Director of e/MTIC: the Eindhoven MedTech Innovation center, a research collaboration of Maxima Medical Center, Kempenhaeghe, Catharina Hospital. Philips and TU/e, with the ambition to bring innovation in the field of Sleep, Perinatal and Cardio-vascular.
View Profile
Close
close
Jakub Hlávka
Director of the Health Economics, Policy and Innovation Institute (HEPII) at Masaryk University, Czech Republic
Jakub Hlávka, Ph.D. is the Director of the Health Economics, Policy and Innovation Institute (HEPII) at Masaryk University, Brno, Czech Republic, Clinical Associate Professor (Adjunct) of Population and Public Health Sciences at the University of Southern California (USC) and Founder of the non-profit Initiative for Effective Healthcare based in the Czech Republic. He also serves as the Healthcare Advisor to the President of the Czech Republic. His research focuses on health system sustainability, Alzheimer’s disease and access to innovative technologies in healthcare. Jakub holds holds a PhD degree from the RAND School of Public Policy, a master’s degree from Georgetown University, Edmund A. Walsh School of Foreign Service, and an undergraduate degree from the University of Economics in Prague. He has studied and worked in the Czech Republic, United States, United Kingdom and Germany and enjoys classical music and triathlon in his free time.
View Profile
Close
close
Michio Tanaka
VP, Medical, AstraZeneca, United Kingdom
Michio joined Zeneca K.K. in 1997 as a member of Japan Product Team for compounds in breast cancer area. Upon the approval of Arimidex® for treatment of breast cancer in year 2000, he led the regulatory strategy through the bridging study utilizing overseas clinical data which was the first case in Japan. He has worked extensively in regulatory, clinical development, and pharmacovigilance. He also holds vast experience negotiating with regulatory agency. He successfully negotiated local development initiation of Nexium® and intranasal flu vaccine with the regulatory agency, which had been dead stocks in the Japanese product pipeline due to difficulties in gaining agreement from the agency.
Since 2009, Michio has led a global team responsible for the development of early-stage oncology compounds at the AstraZeneca, Macclesfield UK, where is home of the Product Strategy Team and supply chain. He also has developed an alliance management framework for co-development with other companies and academia during his time in the UK.
He returned to Japan in 2013 being responsible for product development in the areas of oncology, neuroscience, and infectious diseases in R&D. Remarkably he brought a new paradigm of flu vaccine development by delivering the first ever largest clinical study locally.
Became Head of Science & Data Technology Division in 2016 and has made significant operational contributions to the company in addition to his contribution to strategic aspects, including the introduction of the new CTD (Common Technical Document) structure to enable minimizing the time gap between US/Europe and Japan while filing new drug applications as well as leading a collaboration with National Institute of Communication and Technology (NICT) and pharma peers to adapt a neural machine translation engine to pharmaceutical and global drug development.
From year 2020 to 2022, as the Japan Lead for the pandemic vaccine project, he directed the entire project for the COVID-19 vaccine, Vaxzevria™, including the signing of the supply agreement with the Japanese government, establishment of the local manufacturing scheme, and its emergency regulatory approval.
He was appointed VP of Medical in September 2022. He has contributed to the implementation of the "J-Pathway Study," Japan's first nationwide study utilizing the National Cancer Registry Information," and achieved Japan's first certification as an "Accredited Pseudonymous Medical Information User" based on the Next-Generation Medical Infrastructure Law. Through these initiatives, he has been leading our data generation efforts.
View Profile
Close
close
Charmaine Gauci
Superintendent of Public Health and Director General of Health Regulation at the Ministry for Health, Malta
Professor Charmaine Gauci is the Superintendent of Public Health and Director General for Public Health within the Ministry for Health and Active Ageing in Malta with wide responsibility of public health to safeguard and enhance the health status of the people. She had previously occupied the position of Director of the Health Promotion and Disease Prevention Directorate for nine years.
She graduated as a medical doctor in 1991. Over the years she has developed skills in the wide aspect of the public health specialty. She pursued her studies with MSc in public health and consequently followed the European Programme in Epidemiological Training. She attained her PhD Degree in epidemiology in 2006. Dr Gauci is also a Prince practitioner in project management. She is a fellow of the UK Royal Society for Public Health and a fellow of the UK Faculty of Public Health.
Professor Gauci is a professor at the University of Malta and delivers lectures in public health with special interest in Public Health, Epidemiology, Communicable Diseases, Health Promotion and Policy development. She is an advocate for public health having served as secretary, vice president and president of the Malta Association of Public Health Medicine for four years.
Professor Gauci acts as a focal point for a number of bodies within the European Commission including ECDC and Health Security and for the World Health Organisation.
Profs Gauci has led the public health response to the COVID-19 pandemic in her capacity of SPH. On Republic Day, 13th December 2020, the President, on behalf of the government and people of Malta, paid her public tribute for distinguishing herself in the work on the pandemic and appointed her in the grade of officer to The National Order of Merit. This is the state order of the Republic of Malta.
Her aim is to protect, support and improve people’s health and wellbeing.
View Profile
Close
close
Marwan Al Kaabi
Chief Executive Officer - Sheikh Shahbout Medical City, a PureHealth Entity Company,United Arab Emirates
Dr. Marwan Al Kaabi is the chief executive officer (CEO) of Sheikh Shakhbout Medical City(SSMC). With over 17 years of hands-on experience in successfully leading comple operations and large teams, Dr. Al Kaabi has earned a reputation as an expert in driving operational efficiency, improving customer care and enterprise risk management. Before joining SSMC, Dr. Al Kaabi held the position of chief of critical infrastructure management and response at PureHealth, where he played a pivotal role in safeguarding critical infrastructure. His role included developing and implementing incident and crisis management plans and establishing stringent security protocols and health and safety standards.
Dr. Al Kaabi also served as the chief operations officer (COO) at Abu Dhabi Health Services Company (SEHA), where his visionary leadership steered the organisation through multiple strategic initiatives. Driven by a commitment to advancing healthcare delivery, Dr. Al Kaabi brings a wealth of experience and a proven track record of success to SSMC. Additionally, he serves on the Advisory Board of the United Arab Emirates University and has recently joined the Leaders Advisory Board of the Arab Hospitals Federation.
Dr. Al Kaabi is a Medical Doctor (M.D.) and holds a Master’s degree in Health Emergency Management from Boston University, as well as an executive certificate in Managing Healthcare Delivery from Harvard Business School. His academic pursuits have equipped him with extensive experience in both medical practice and healthcare management.
View Profile
Close
close
Prof. Dr. Eng. Ionescu Octavian
Romanian's National Institute for Research and Development for Microtechnologies
Professor Dr Eng Ionescu Octavian is an experienced researcher working at Romanian's National Institute for Research and Development for Microtechnologies. He is also lecturing at Petroleum and Gas University from Ploiesti. Professor Ionescu held 4 USPTO, 1EPO, and 5 national patents, authored over 65 WOS indexed articles.
View Profile
Close
close
Health and Well-being Week
Agenda2025 business exchange programme‘Visionary Exchange'
We are pleased to organise a speech and discussion event, as well as a lunch networking event, on the theme of the Agenda programme ‘Health and Well-being’, entitled ‘Visionary Exchange’, as part of the Agenda2025 programme.This gathering aims to include business delegations, universities, scientists, government officials, Agenda2025 panelists, and relevant Japanese leaders from government, industry, and academia. Participants will engage in keynote addresses and networking sessions aligned with each Theme's focus.（Invitation only）
-
2025.06.27[Fri]
10:30～13:30
(Venue Open 10:00)
- EXPO Salon
- * Programme times and content are subject to change. Any changes will be announced on this website and via the ticket booking system.
- * The schedule is subject to change depending on the organiser's circumstances.
This programme is invitation only.
OTHER PROGRAM
Health and Well-being Week
